NCT06873763 - Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2027

Conditions

Metastatic Colorectal Cancer (CRC)Recurrent Colorectal Cancer

Interventions

DRUG

Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab

Trifluridine/tipiracil is dose-deescalated from 35 mg/m² to 30 mg/m² and 25 mg/m² to determine the RP2D, in combination with fixed doses of Nelmastobart and Bevacizumab, in patients with metastatic colorectal cancer who are refractory or intolerant to prior oxaliplatin- and irinotecan-based chemotherapy.

Trial Locations (5)

13620

NOT_YET_RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

03080

NOT_YET_RECRUITING

Seoul National University Hospital, Seoul

03722

NOT_YET_RECRUITING

Severance Hospital, Seoul

05505

NOT_YET_RECRUITING

Asan Medical Center, Seoul

02841

RECRUITING

Korea University Anam Hospital, Seoul

All Listed Sponsors

lead

STCube, Inc.

INDUSTRY